TET2 mutations have also been reported in up to 28% of MDS and myeloproliferative neoplasms (15, 20, 49) and up to 50% of angioimmunoblastic T cell lymphoma (AITL), where they are associated with poor response to anthracycline-based chemotherapy (50). This evidence concerns the gene TET2 and angioimmunoblastic T-cell lymphoma.